Uncoupling CD4+ TIL-mediated tumor killing from JAK-signaling in melanoma.
Arianna DraghiMario PrestiAgnete Witness Præst JensenChristopher Aled ChamberlainBenedetta AlbieriAnne-Christine K RasmussenMads Hald AndersenMichael Douglas CrowtherInge Marie SvaneMarco DoniaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
In conclusion, our data indicate that exploiting tumor-specific cytotoxic CD4+ TILs could help overcome resistance to ICB mediated by IFNγ-signaling loss in MHCIIconst+ melanomas.